September 21, 2020


SAFE-N-MEDTECH OITB project gathers 28 partners from around the world and focuses its activity in enabling the safe translation of nano-enabled medical technologies from “proof-of-concept” to markets and clinical practice.

The sudden COVID-19 outbreak has meant an unforeseen challenge that requires rapid answers from the Science, Technology and Innovation Community. Consequently, three European Union-funded MedTech Open Innovation Testbed (OITB) projects – SAFE-N-MEDTECH, TBMED and MDOT – decided to work together to provide services to selected innovators and help them reach the market faster.

The three OITB projects have allocated part of their budgets to include new case studies in their on-going projects. Innovative SMEs, companies, start-ups and applied research institutions working on the development of solutions to fight the virus are invited to apply to this call. And, the concept of OITBs to forge pan-European innovation networks tailored to the specific needs of novel medical technologies makes them the ideal instruments for quickly finding solutions under urgent conditions such as the COVID-19 outbreak.

The call for expressions of interest from MedTech SMEs performing COVID-19-related developments is now open and support will be provided in the following ways:

  • First evaluation of the project/product based on Health Technology Assessment (HTA) and Healthcare system needs to be provided by our pool of experts

  • Technology scanning to identify redundancies/synergies

  • Nanomaterial characterisation

  • In vitro preclinical research

  • Access to clinical samples and Biobanks

  • Assistance in prototyping and qualification of manufacturing facilities

  • Regulatory advice and support in the adapted European regulation for COVID 19 medical technologies

  • Links to clinical networks

  • Business development coaching, links with business angels, investors, capital risk, etc.

Typically, the project will cover costs related to the activities mentioned above, according to the budget limits available. If outstanding expenses beyond the available budget are needed, these will need to be covered by the user. The project won’t be able to cover formal regulatory costs, production costs, clinical development costs or any external costs that might be needed for the testing and production of the nano-enabled Medical Technologies. 

Please note that all information provided will be treated confidential and is stored only for the purpose of this call. The submission deadline: October 2nd, 2020, 5:00 p.m. CET. Applicants will be informed about the outcome of their application in mid-October. Activities are envisaged to start the beginning of November.